There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immatics (IMTX – Research Report), Omega Therapeutics (OMGA – Research Report) and Roivant Sciences (ROIV – Research Report) with bullish sentiments.
Immatics (IMTX)
In a report released yesterday, Kelly Shi from Jefferies maintained a Buy rating on Immatics, with a price target of $20.00. The company’s shares closed last Wednesday at $11.51.
According to TipRanks.com, Shi has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immatics with a $18.75 average price target, a 68.0% upside from current levels. In a report issued on September 11, Mizuho Securities also reiterated a Buy rating on the stock with a $14.00 price target.
See the top stocks recommended by analysts >>
Omega Therapeutics (OMGA)
In a report released yesterday, Roger Song from Jefferies maintained a Buy rating on Omega Therapeutics, with a price target of $15.00. The company’s shares closed last Wednesday at $2.40, close to its 52-week low of $2.27.
According to TipRanks.com, Song has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Omega Therapeutics with a $11.80 average price target.
Roivant Sciences (ROIV)
In a report released yesterday, Dennis Ding from Jefferies maintained a Buy rating on Roivant Sciences, with a price target of $16.00. The company’s shares closed last Wednesday at $12.90.
According to TipRanks.com, Ding is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Roivant Sciences with a $16.57 average price target, implying a 33.5% upside from current levels. In a report released yesterday, Goldman Sachs also maintained a Buy rating on the stock with a $16.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IMTX:
- Moderna, Immatics announce strategic multi-platform collaboration
- Immatics files to sell 2.42M ordinary shares for holders
- Immatics Announces Second Quarter 2023 Financial Results and Business Update
- Immatics reports Q2 EPS (32c), consensus (27c)
- Immatics initiates Phase 1/2 trial to evaluate PRAME TCR bispecific IMA402
